Fenbendazole 500 mg – Pharmaceutical-Grade Oral Tablet (Per Box)

Fenbendazole 500 mg is a broad-spectrum benzimidazole compound originally developed as an antiparasitic medication for veterinary use. In recent years, it has attracted attention for its off-label investigational role in integrative cancer support protocols, leveraging its unique mechanism of action.

This human-use formulation provides pharmaceutical-grade purity, making it suitable for research-based or physician-supervised protocols in integrative oncology.

Uses of Fenbendazole 500 mg

Investigational / Research Use

• Part of integrative cancer support protocols

• Used in combination strategies such as the Shakman Protocol, which may include antiparasitic agents, antibiotics, and immune modulators

• Designed for physician-supervised or research-based administration

Mechanism of Action

Fenbendazole works by interfering with cellular microtubule formation, which affects parasitic survival and metabolism. In investigational cancer protocols, it may impact cellular metabolic and structural pathways under medical supervision.

Dosage & Administration

• Intended for physician-guided or research use

• Tablets are taken orally with water, preferably after meals

• Dosage is determined by protocol requirements or medical supervision

Common Side Effects

• Mild nausea or gastrointestinal discomfort

• Temporary fatigue

• Rare headaches

Serious Side Effects

• Allergic reactions including rash, swelling, or difficulty breathing

• Persistent vomiting or abdominal discomfort

• Liver function changes with prolonged use

Precautions & Warnings

• Not FDA-approved for cancer treatment

• Use only under medical guidance or research supervision

• Avoid in individuals with known benzimidazole allergy

• Not recommended during pregnancy or breastfeeding